Alyssa Eisenberg, PharmD, explores technology’s emerging role in the health care environment and how the pharmacist of the future’s day-to-day tasks might evolve.
|Articles|January 24, 2005
Here comes the judge
What do the Kansas City pharmacist Robert Courtney, Doc's Pharmacy in Walnut Creek, Calif., and Vioxx (rofecoxib, Merck) have in common? All involve pharmaceuticals, pharmacies, claims of harm to patients—and lawsuits against pharmacists.
Advertisement
Advertisement
Related to this article
In the final portion of our discussion with Kimberly Kue-Tsemo, PharmD, she explores the key developments that could be the most significant push toward reducing pharmacy deserts.
In the second part of our interview with a collection of pharmacists from various backgrounds, they delve into the current developments highlighting the future of the profession.
Phase 2 trial results for the investigational vaccine were presented at IDWeek 2026 in Washington, DC, as the phase 3 program is currently underway.
The finalized rule is another step in the right direction for pharmacies calling for reform due to underwater reimbursement and other PBM pressures.
Allison Schneider, MPH, provides a detailed update regarding pharmacies’ impact within Medicare price negotiations and the legislation further impacting businesses.
The US health department announced policies that will allow for the compounding of 6 key peptides in US pharmacies.
New survey data add to the evidence regarding the safe and effective route of administering both COVID-19 and flu vaccines simultaneously.
Advertisement
Advertisement
Trending on Drug Topics
1
American Pharmacists Month: Technology’s Role in Expanding Pharmacist Scope
2
PBMs Must Now Disclose Fees to Employer Plans Under Final DOL Rule
3
American Pharmacists Month: PBM Reform, Provider Status Key in Stopping Pharmacy Deserts
4
HHS Lets Pharmacies Compound Peptides as FDA Writes Official Rule
5